Kenneth S. Warren Institute: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m I added the new address for Warren Pharmaceuticals as of Jan 2018.
Tomvet (talk | contribs)
5 edits
The Institute is still active. Anthony Cerami retired and Carla Cerami, MD, PhD took over as chairperson. References to Warren Pharmaceuticals (which closed in 2021) and funding from Lundbeck are not relevant to the Warren Institute.
Line 1: Line 1:
'''The Kenneth S. Warren Institute''' is a not-for-profit organization based in Durham, North Carolina that as of 2017 appears to be defunct.<ref>{{cite web|title=Profile:The Kenneth S Warren Institute Inc |url=https://www2.guidestar.org/profile/13-3054365|publisher=GuideStar|accessdate=26 July 2017|language=en}}</ref><ref>{{cite web|title=Profile:The Kenneth S Warren Institute Inc |url=https://npoindex.com/133054365|publisher=npoindex.com|accessdate=26 July 2017}}</ref>
'''The Kenneth S. Warren Institute''' is a not-for-profit organization based in Durham, North Carolina.<ref>{{cite web|title=Profile:The Kenneth S Warren Institute Inc |url=https://www2.guidestar.org/profile/13-3054365|publisher=GuideStar|accessdate=26 July 2017|language=en}}</ref><ref>{{cite web|title=Profile:The Kenneth S Warren Institute Inc |url=https://npoindex.com/133054365|publisher=npoindex.com|accessdate=26 July 2017}}</ref> It is named after Kenneth Warren (June 11, 1929 – September 18, 1996), a powerful figure in twentieth century medicine whose work transformed public health policy and tropical medicine, and who left a profound legacy in global health thinking.<ref>{{Cite book|last=Keating|first=Conrad|url=https://www.springer.com/gp/book/9783319501451|title=Kenneth Warren and the Great Neglected Diseases of Mankind Programme|publisher=Springer|year=2017|isbn=978-3-319-50147-5|location=https://doi.org/10.1007/978-3-319-50147-5}}</ref><ref>{{Cite web|title=Kenneth S Warren|url=https://en.wikipedia.org/wiki/Kenneth_S._Warren|url-status=live|website=Wikipedia}}</ref> The Institute was incorporated as a not-for-profit foundation, under the New York State Not-for-Profit laws and Internal Revenue Code [Section 501 (c)(3)], and was originally chartered in 1980, under the name of The Drug and Vaccine Development Corporation (“DVDC”).  In response to a U.S. government mandate on the industrial sector to contribute more directly to improving public health in emerging nations, the DVDC espoused to pay particular attention to health problems affecting populations in the developing world. It sought to promote work in the fields of parasitology and tropical medicine.


It had been based in [[Tarrytown, New York]], and in 2001, the institute bought a {{convert|15|acre|m2|sing=on}} campus located in [[Westchester County]], New York from the Kitchawan Institute.<ref>{{cite news|last1=Worth|first1=Robert|title=Kitchawan Institute to Sell Center to a Research Group|url=https://www.nytimes.com/2001/04/08/nyregion/in-business-kitchawan-institute-to-sell-center-to-a-research-group.html|work=The New York Times|date=8 April 2001}}</ref> At that time its director and lead researcher was [[Anthony Cerami]], and it was a medical research institute that had been doing research related to [[erythropoietin]] derivatives they called "tissue protective cytokines".<ref name=Startup/><ref name=LicensePR>{{cite web|title=Press release: Lundbeck Announces License Agreement And Equity Investment In Warren Pharmaceuticals {{!}} Evaluate|url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=21454|publisher=Lundbeck and Warren Pharmaceuticals via Evaluate|date=February 18, 2002}}</ref> They also said that they coordinated with researchers who were working on vaccines for [[neglected tropical diseases]].<ref>{{cite news|last1=Vittachi|first1=Imran|title=Yorktown|work=The Journal News [White Plains, N.Y]|date=6 April 2001|page=B.4}}</ref> Cerami has been president and trustee of an organization called the "Kenneth S. Warren Laboratories, Inc." as of March 1998.<ref>{{cite web|title=Alteon 10-K For the fiscal year ended December 31, 1997|url=https://www.sec.gov/Archives/edgar/data/878903/0000893220-98-000631.txt|publisher=Alteon via SEC Edgar|date=March 31, 1998}}</ref>
In 2001, the institute bought a {{convert|15|acre|m2|sing=on}} campus located in [[Westchester County]], New York from the Kitchawan Institute (also known as the Weston Charitable Foundation).<ref>{{cite news|last1=Worth|first1=Robert|title=Kitchawan Institute to Sell Center to a Research Group|url=https://www.nytimes.com/2001/04/08/nyregion/in-business-kitchawan-institute-to-sell-center-to-a-research-group.html|work=The New York Times|date=8 April 2001}}</ref> The campus and surrounding nature preserve was the Kitchawan Research Station of the Brooklyn Botanical Gardens. The director and lead researcher was [[Anthony Cerami]]. Funding from the Burroughs Wellcome Fund for malaria research was granted to scholars at the institute. Collaborative work with the Neuroscience INstitute in Milan (previusly the part of the Italian National Research Council).<ref>{{Cite web|title=Istituto di Neuroscienze|url=http://www.in.cnr.it/index.php/en/component/content/article/26-people/people-cagliari/40-giancarlo-colombo-en|url-status=live}}</ref> Researchers at the institute looked at erythropoietin as a tissue-protective cytokine in brain injury<ref>{{Cite journal|date=2005|title=Emerging biological roles for erythropoietin in the nervous system|url=https://doi.org/10.1038/nrn1687|journal=Nature reviews. Neuroscience.|volume=6|pages=484-494}}</ref> and eventually developed non-erythropoietic small peptides for innate protection and repair of tissues from inflammation.<ref>{{Cite journal|date=2015|title=Flipping the molecular switch for innate protection and repair of tissues: long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.|url=https://doi.org/https://10.1016/j.pharmthera.2015.02.005|journal=Pharmacology & therapeutics.|volume=151:32-40|pages=32-40|via=Elsevier}}</ref>


The Kitchawan facility was for sale as of 2014.<ref>{{cite web|title=712 Kitchawan Road, Ossining, NY 10562 - LoopNet Property Records|url=http://www.loopnet.com/Property-Record/712-Kitchawan-Road-Ossining-NY-10562/L9a5DwJ0Q/Sale-Lease/|publisher=LoopNet|accessdate=26 July 2017}}</ref>
The institute moved from Westchester to the Research Triangle (Raleigh-Durham-Cary in N Carolina) in 2014.<ref>{{cite web|title=712 Kitchawan Road, Ossining, NY 10562 - LoopNet Property Records|url=http://www.loopnet.com/Property-Record/712-Kitchawan-Road-Ossining-NY-10562/L9a5DwJ0Q/Sale-Lease/|publisher=LoopNet|accessdate=26 July 2017}}</ref> The institute continues it's research and collaborates with the MRC Unit The Gambia at LSHTM.<ref>{{Cite web|date=2020|title=About MRC Unit The Gambia at LSHTM|url=https://www.mrc.gm/about-us/|url-status=live}}</ref>

In 2001, Warren Pharmaceuticals was formed to commercialize inventions made at the institute, starting with the cytokines, with funding from [[Lundbeck]] and a Danish bank; Cerami was chairman of the board.<ref name=Startup>{{cite journal|title=Warren Pharmaceuticals|journal=Startup Magazine|issue=October 2004|pages=39–41}}</ref><ref name=LicensePR/><ref>{{cite news|title=Warren Pharmaceuticals, Inc. Announces Founding Members Of the Board of Directors and Management|publisher=Warren Pharmaceuticals, Inc. via PR Newswire|date=August 1, 2002|quote=Chairman of the Board, Anthony Cerami, PhD, is Director of The Kenneth S. Warren Institute. ... Warren Pharmaceuticals, Inc. is a private biotechnology company incorporated in 2001 to develop and commercialize certain patented tissue-protective technologies, focusing on the therapeutic areas of the eye and the cardiovasculature}}</ref> In 2001, the company licensed the cytokines to Lundbeck in the field of central and peripheral nervous system disorders.<ref name=Startup/><ref>{{cite web|title=Warren Pharmaceuticals: Our Company|url=http://clarkandpartners.com/pages/company.html|publisher=Clark and Partners|archiveurl=https://web.archive.org/web/20160402171357/http://clarkandpartners.com/pages/company.html|archivedate=April 2, 2016}}</ref> The development program was terminated in 2007.<ref>{{cite web|title=Research programme: tissue protection technology - Lundbeck/Warren Pharmaceuticals -|url=http://adisinsight.springer.com/drugs/800017791|publisher=AdisInsight|accessdate=26 July 2017|language=en}}</ref>The current address for Warren Pharmaceuticals is 520 White Plains Road, Suite 500, Tarrytown, NY 10591.


== References ==
== References ==

Revision as of 15:29, 5 October 2021

The Kenneth S. Warren Institute is a not-for-profit organization based in Durham, North Carolina.[1][2] It is named after Kenneth Warren (June 11, 1929 – September 18, 1996), a powerful figure in twentieth century medicine whose work transformed public health policy and tropical medicine, and who left a profound legacy in global health thinking.[3][4] The Institute was incorporated as a not-for-profit foundation, under the New York State Not-for-Profit laws and Internal Revenue Code [Section 501 (c)(3)], and was originally chartered in 1980, under the name of The Drug and Vaccine Development Corporation (“DVDC”).  In response to a U.S. government mandate on the industrial sector to contribute more directly to improving public health in emerging nations, the DVDC espoused to pay particular attention to health problems affecting populations in the developing world. It sought to promote work in the fields of parasitology and tropical medicine.

In 2001, the institute bought a 15-acre (61,000 m2) campus located in Westchester County, New York from the Kitchawan Institute (also known as the Weston Charitable Foundation).[5] The campus and surrounding nature preserve was the Kitchawan Research Station of the Brooklyn Botanical Gardens. The director and lead researcher was Anthony Cerami. Funding from the Burroughs Wellcome Fund for malaria research was granted to scholars at the institute. Collaborative work with the Neuroscience INstitute in Milan (previusly the part of the Italian National Research Council).[6] Researchers at the institute looked at erythropoietin as a tissue-protective cytokine in brain injury[7] and eventually developed non-erythropoietic small peptides for innate protection and repair of tissues from inflammation.[8]

The institute moved from Westchester to the Research Triangle (Raleigh-Durham-Cary in N Carolina) in 2014.[9] The institute continues it's research and collaborates with the MRC Unit The Gambia at LSHTM.[10]

References

  1. ^ "Profile:The Kenneth S Warren Institute Inc". GuideStar. Retrieved 26 July 2017.
  2. ^ "Profile:The Kenneth S Warren Institute Inc". npoindex.com. Retrieved 26 July 2017.
  3. ^ Keating, Conrad (2017). Kenneth Warren and the Great Neglected Diseases of Mankind Programme. https://doi.org/10.1007/978-3-319-50147-5: Springer. ISBN 978-3-319-50147-5. {{cite book}}: External link in |location= (help)CS1 maint: location (link)
  4. ^ "Kenneth S Warren". Wikipedia.{{cite web}}: CS1 maint: url-status (link)
  5. ^ Worth, Robert (8 April 2001). "Kitchawan Institute to Sell Center to a Research Group". The New York Times.
  6. ^ "Istituto di Neuroscienze".{{cite web}}: CS1 maint: url-status (link)
  7. ^ "Emerging biological roles for erythropoietin in the nervous system". Nature reviews. Neuroscience. 6: 484–494. 2005.
  8. ^ "Flipping the molecular switch for innate protection and repair of tissues: long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin". Pharmacology & therapeutics. 151:32-40: 32–40. 2015 – via Elsevier.
  9. ^ "712 Kitchawan Road, Ossining, NY 10562 - LoopNet Property Records". LoopNet. Retrieved 26 July 2017.
  10. ^ "About MRC Unit The Gambia at LSHTM". 2020.{{cite web}}: CS1 maint: url-status (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Kenneth_S._Warren_Institute&oldid=1048352894"